FDA Embraces AI: Generative System to Be Fully Operational by June's End

May.09.2025
FDA Embraces AI: Generative System to Be Fully Operational by June's End
FDA plans to fully integrate a generative AI system across its centers by June 30, 2025. This follows the successful completion of an initial pilot, marking a shift in the agency's approach to regulatory processes. The AI tools are expected to streamline the drug approval process, which typically takes six to ten months, by reducing time spent on repetitive tasks.

Key points:

 

1.The United States Food and Drug Administration (FDA) has officially completed its first AI-assisted scientific review pilot.

 

2.The entire AI system across all departments will be fully deployed by June 30, 2025, covering all centers.

 

3.The goal of AI applications is to reduce the repetitive work of reviewers and improve the efficiency of evaluating new therapies.

 

4.The system is being jointly promoted by the FDA's newly appointed Chief AI Officer Jeremy Walsh and Senior Information Officer Sridhar Mantha.

 

5.Further optimizations will continue to be made to ensure information security and meet the business requirements of each center.

 


 

The U.S. Food and Drug Administration (FDA) announced on May 8 that it has successfully completed its first pilot program using generative artificial intelligence (AI) for scientific evaluation, and will fully deploy a unified AI system across all its centers by June 30. The initiative, led by FDA Commissioner Martin A. Makary, aims to systematically improve internal scientific review efficiency and reduce the workload of professionals on repetitive tasks.

 

"We need to highly value the time of scientists and reduce redundant processes. The widespread application of AI technology can significantly accelerate the speed of reviewing new therapies."

 

At the same time, he emphasized that the deployment operation this round will be based on the basic principles of "fast, unified, and safe," and will comprehensively establish interfaces between the evaluation data platform and AI tools.

 

The pilot project uses generative AI technology specifically designed for FDA scientists and experts, with a focus on reducing inefficient, repetitive labor. Jinzhong (Jin) Liu, Deputy Director of the Office of New Drug Review at the FDA Center for Drug Evaluation and Research (CDER), said the tool can complete a task that originally took three days in just a matter of minutes, calling it a "transformative technology.

 

According to deployment arrangements, all FDA centers have received instructions to immediately initiate internal deployment. June 30th is the timeline for the first round of full system launch, at which time each center will carry out AI-assisted work based on a unified platform deeply integrated with FDA internal data structures. After deployment, FDA will continue to optimize functions, expand specific application scenarios, and ensure that each center can customize their usage paths based on their own business characteristics.

 

The program is led by Jeremy Walsh, the newly appointed Chief AI Officer at the FDA. Walsh has previously overseen major technology deployments at various federal health and intelligence agencies. He is partnered with Sridhar Mantha, who formerly served as the head of the CDER Business Informatics Office. Together, they will collaborate on advancing overall AI deployment, user training, system security, and ongoing performance assessments throughout the agency.

 

The FDA announced that more details will be released in June and progress updates will be made public. The agency also promised to continuously iterate AI tools through user feedback mechanisms to ensure they are closely aligned with regulatory tasks and assist in the mission of promoting public health.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

South Korea's Synthetic Nicotine Tax Take Estimated at Just 1.3% of Forecast as Imports Plunge Nearly 97%
South Korea's Synthetic Nicotine Tax Take Estimated at Just 1.3% of Forecast as Imports Plunge Nearly 97%
After synthetic nicotine was placed under tobacco regulation on April 24, 2026, South Korea’s tax collections from synthetic-nicotine vaping products fell far short of government projections. The Chosun Ilbo reported on November 18 that Ministry of Health and Welfare data showed national health promotion charges on synthetic-nicotine liquid e-cigarettes totaled 765 million won from April 24 through September. Using statutory rates, the newspaper estimated combined major taxes and charges at about 2.622 billion won—on a monthly basis roughly 1.3% of an earlier forecast after temporary tax reductions. Customs data showed synthetic-nicotine imports dropped from about 1,467 metric tons in January–April to 45 metric tons in May–August, a nearly 97% decline. Imports of nicotine-analog and nicotine-free liquids totaled 151 metric tons in May–August, exceeding synthetic-nicotine imports in the same period, though both categories were also below January–April volumes.
Regulations
Nov.19
German Customs Seize 115,800 Vapes in €1.4 Million Tax Case
German Customs Seize 115,800 Vapes in €1.4 Million Tax Case
Germany's Magdeburg Main Customs Office seized 115,800 untaxed e-cigarettes containing a combined 4.366 million mL of e-liquid during four truck inspections between August 10 and September 4, 2026. The seizures prevented an estimated €1.397 million in tax losses and set a record for the customs office's jurisdiction. Criminal proceedings have been initiated against four truck drivers. The case follows a separate German investigation involving more than 7.6 million illicit vapes and an estimated €33.3 million in excise-tax losses.
Enforcement
Oct.13
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds American says nearly 183,000 U.S. retail outlets are under contract, with its Retail Marketing Plan Contract covering about 94% of company volume and requiring point-of-sale age verification. The company combines those contracts with We Card, TruAge, NACS-linked infrastructure and POS integration, while enhanced Vuse Pro retail rules add ID scanning, purchase limits and stronger underage-sales accountability. The initial Vuse Pro rollout targets about 50,000 stores. The system is taking shape as unauthorized vapor products remain dominant in parts of the U.S. market: a 2026 study estimated they accounted for 69.4% of tracked brick-and-mortar e-cigarette dollar sales in December 2025.
Special Report
Oct.15
Brad Rodu Says Declining Cigarette Smoking Is Key to Tobacco Harm Reduction | 2Firsts Interview
Brad Rodu Says Declining Cigarette Smoking Is Key to Tobacco Harm Reduction | 2Firsts Interview
After more than 30 years researching tobacco harm reduction, University of Louisville professor Brad Rodu says opposition to smoke-free alternatives still surprises him. In an exclusive 2Firsts interview in Manila, he argued that declining smoking rates represent progress even if nicotine use rises, discussed nicotine and cancer, and examined Sweden's snus experience and youth vaping. Rodu welcomed recent FDA decisions but criticized slow reviews and poor risk communication. He called a change in the WHO's stance potentially significant, while doubting it would happen soon.
Nov.20
DATA|UK Retail Research Group IGD Says Convenience Tobacco and Vape Sales Fell 10.6%, With 15.4% Market Share Versus Alcohol's 15.1%; Top Rank at Risk in 2027
DATA|UK Retail Research Group IGD Says Convenience Tobacco and Vape Sales Fell 10.6%, With 15.4% Market Share Versus Alcohol's 15.1%; Top Rank at Risk in 2027
Combined tobacco and vaping sales in UK convenience stores fell 10.6% year over year in the first half of 2026, making the category a major drag on channel performance, according to retail research organization IGD. Total convenience sales declined 1.2%, while sales excluding tobacco and vaping increased 0.7%. IGD's 2026 category-share figures show tobacco and vaping accounting for 15.4% of convenience sales, compared with 15.1% for alcohol. The organization forecasts alcohol could overtake tobacco and vaping as the largest category by sales value as early as 2027 if current trends continue. IGD expects the convenience market to increase from £48.6 billion in 2026 to £54.9 billion in 2031, a 2.5% compound annual growth rate, or 3.4% excluding tobacco and vaping.
DATA
Nov.11
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26